08:00 | Registration |
|
Session Chair: Tim Hammonds, Deputy Director Drug Discovery, Cancer Research Technology, UK |
| |
09:00 | The IMI European Lead Factory: New Opportunities for Drug Discovery
Phil Jones, Director, European Screening Centre Newhouse, University of Dundee, United Kingdom
This talk will explain the background and current status of this project and highlight opportunities to participate. |
09:45 |  | Keynote Presentation Structural Biology and Drug Discovery: Targeting Protein-Protein Interfaces
Sir Tom Blundell, Professor, University of Cambridge, United Kingdom
Targeting protein-protein interfaces of multiprotein assemblies offers opportunities for improving specificity and selectivity in drug discovery. I will describe computational analyses of protein interface landscapes for multiprotein assemblies and exemplify use of fragment-based approaches for two very different PPI targets. |
|
10:45 | Coffee and Networking in Exhibition Hall |
11:15 | Successful Examples of Commercialising Academic Drug Discovery Projects
Patrick Chaltin, Director, K U Leuven Research & Development, Belgium
Many drugs find their origin within academic research. Examples from the past show that there are many different ways by which academic discoveries get commercialised. Recently, translational drug discovery centers have taken up the challenge and are delivering successes. |
12:00 | Promoting Apoptosis To Treat Cancer
Kurt Deshayes, Senior Scientist, Early Discovery Biochemistry, Genentech, United States of America
|
12:45 | Lunch & Networking in Exhibition Hall |
14:30 | Interacting with pharma Open Innovation, What to Expect and What is Expected
Niclas Nilsson, Open Innovation Manager, LEO Pharma, Denmark
The presentation will describe the science behind LEO Pharma’s Open Innovation platform and how it can catalyze pre-competitive collaborations by allowing external access to test compounds in disease-relevant assays. |
15:15 | Development of Chemical Probes for Studying Cancer
John Spencer, Professor, University of Sussex, United Kingdom
We will present the synthesis of privileged structure libraries and their applications against a range of biological targets. |
16:00 | Coffee and Networking in Exhibition Hall |
16:30 | Enabling Open Innovation Drug Discovery Partnerships
Garry Pairaudeau, Global Head of Research Outsourcing, AstraZeneca, United Kingdom
The presentation will cover AstraZeneca’s approaches to open innovation, particularly focussing on sharing components of our compound collection in order to generate starting points for academic drug discovery projects. It will describe some of the background to the compound collection and the strategy and investment that has gone into it over the past decade in order to create such a valuable screening resource. It will also discuss innovative options for sharing compounds and ways partners can access the AstraZeneca screening infrastructure to identify relevant biological activity in their molecules. |
17:15 | Chemical Probes to Explore Epigenetic Targets
Susanne Muller Knapp, Group Head Structural Genomics Consortium (SGC), University Of Oxford, United Kingdom
Chemical probes, well-characterized, potent, selective and cell-active tool compounds, are essential tools in biology and target validation. More than 30 probes against epigenetic targets have been developed by the SGC and provided to the scientific community, which greatly accelerated research in this area. |
18:00 | End of Day One |
